Home / Research library / ACE-031
ACE-031: molecular data, studies & sources
ACE-031 is catalogued here as an identity or preparation requiring extra specification. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
Molecular record not yet resolved
ACE-031 is a recombinant fusion protein. A validated sequence and glycosylation specification are needed for preparation-specific molecular data.
MF: not assigned · MW: not assigned · Structure: not assigned
Registered clinical trials
Studies registered on ClinicalTrials.gov that list ACE-031 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
4 registered studies matched, 1 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 2 · 2Phase 1 · 2
- By registry status
- Completed · 2Terminated · 2
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyNCT01239758 · start 2010-10 · primary completion 2011-05 | Phase 2TerminatedWhy stopped: This study was terminated based on preliminary safety data. | Duchenne Muscular Dystrophy | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA11 participants |
| Study of ACE-031 in Subjects With Duchenne Muscular DystrophyNCT01099761 · start 2010-04 · primary completion 2011-06 | Phase 2TerminatedResults posted 2016-10-14Why stopped: Based on preliminary safety data. | Duchenne Muscular Dystrophy | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA24 participants |
| A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal WomenNCT00952887 · start 2009-08 · primary completion 2011-02 | Phase 1Completed | Muscular Atrophy | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA70 participants |
| A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal VolunteersNCT00755638 · start 2008-09 · primary completion 2009-07 | Phase 1Completed | Muscle Loss | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA48 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received ACE-031, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.
Attie KM, Borgstein NG, Yang Y et al. · Muscle & nerve · 2013
PMID 23169607 · DOI: 10.1002/mus.23539
- Human study · PubMed trial index Compound given to participants
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
Campbell C, McMillan HJ, Mah JK et al. · Muscle & nerve · 2017
PMID 27462804 · DOI: 10.1002/mus.25268
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
Gel Electrophoretic Detection of Black Market ACE-031.
Reichel C, Filip T, Gmeiner G et al. · Drug testing and analysis · 2025
PMID 40312924 · DOI: 10.1002/dta.3898
ACE-031 supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
ACE-031 for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Cenexa LabsUSD | 1mg Vial1 recorded offers | 1mg Vial · $179.99Checked Nov 6, 2026Supplier listing, ACE-031 1mg Vial, Cenexa Labs, opens in a new tab |
Reference sources & further reading
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Adipotide
C111H206N36O28S2
2557.2 g/mol · PubChem CID 163360068
1 selected publication · 0 human intervention studies
AICAR
C9H14N4O5
258.23 g/mol · PubChem CID 17513
4 selected publications · 3 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 3
B7-33
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
BAM15 Capsules
Molecular identity needs further verification
8 selected publications · 0 human intervention studies
Dermorphin
C40H50N8O10
802.9 g/mol · PubChem CID 5485199
1 selected publication · 1 human intervention study
Enclomiphene
C26H28ClNO
406.0 g/mol · PubChem CID 1548953
5 selected publications · 3 human intervention studies · 22 registered trials
Small molecule · highest stage: Phase 3